The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
With the current crisis related to the emergence of carbapenem-resistant Gram-negative bacteria (CR-GNB), classical treatment approaches with so-called "old-fashion antibiotics" are generally unsatisfactory. Newly approved β-lactam/β-lactamase inhibitors (BLBLIs) should be considered as th...
Saved in:
Main Authors: | Abdullah Tarık Aslan (Author), Murat Akova (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
by: Giacomo Luci, et al.
Published: (2021) -
Revisiting the Checkerboard to Inform Development of β-Lactam/β-Lactamase Inhibitor Combinations
by: Darren J. Bentley
Published: (2024) -
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
by: Anna Duda-Madej, et al.
Published: (2023) -
β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
by: Silvana Alfei, et al.
Published: (2022) -
β-lactam susceptibility in extended-spectrum β-lactamase-producing isolates
by: Gopal Nandlal Agrawal, et al.
Published: (2017)